ITGAV and neoplasm: This could be achieved using peptides or inhibitors that specifically inhibit POSTN-integrin binding, such as peptides targeting CD51 or selective γ-secretase inhibitor LY3039478 (Cai et al., 2023b), thereby attenuating the downstream signaling pathways associated with tumor growth.